Advil vs adyn

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (39 vs 40)
Advil logo

Advil

EmergingHealthcare

General

Global #1 OTC ibuprofen brand owned by Haleon (LSE/NYSE: HLN, GSK 2022 spinoff); Pfizer exited $3B+ stake early 2025 with ADA Seal for Advil Dual Action dental pain competing with Tylenol and Aleve for OTC analgesic market.

AI VisibilityBeta
Overall Score
D39
Category Rank
#432 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
35
Perplexity
40
Gemini
42

About

Advil is a global over-the-counter ibuprofen pain relief brand — owned by Haleon plc (LSE: HLN / NYSE: HLN), the consumer healthcare company spun off from GSK on July 18, 2022, with Pfizer completing its full stake exit in early 2025 for $3+ billion — providing consumers with 23+ ibuprofen-based product varieties for pain, headache, cold, and sleep management including Advil Extra Strength, Advil Rapid Release Gels, Advil PM, Advil Dual Action (ibuprofen + acetaminophen), and Children's Advil. Advil entered the US market in 1984 (the first OTC ibuprofen in America, considered the "most famous prescription-to-OTC switch in history") and generates approximately $800 million+ annually as one of Haleon's flagship brands alongside Sensodyne, Panadol, Centrum, and Theraflu. In September 2024, Advil Dual Action became the first OTC pain reliever to earn the American Dental Association (ADA) Seal of Acceptance for temporary management of acute dental pain.

Full profile
adyn logo

adyn

EmergingHealthcare

General

Precision birth control test using hormone and genetic data to personalize contraceptive selection; $2.65M from Lux Capital and M13 addressing trial-and-error that leaves millions on wrong contraceptives.

AI VisibilityBeta
Overall Score
C40
Category Rank
#385 of 596
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
43
Perplexity
35
Gemini
37

About

adyn is a precision medicine company developing personalized birth control solutions through at-home testing kits that analyze hormone levels and genetic risk factors — enabling individuals to choose hormonal contraceptives based on their own biology rather than trial-and-error, addressing a gap where most people cycle through multiple birth control options over years to find what works without causing intolerable side effects. Founded in 2019 and a Y Combinator graduate, adyn raised $2.65 million in seed funding co-led by Lux Capital and M13, with the Birth Control Optimization Test positioned as the first biology-based test for contraceptive personalization.

Full profile

AI Visibility Head-to-Head

39
Overall Score
40
#432
Category Rank
#385
77
AI Consensus
75
stable
Trend
stable
35
ChatGPT
43
40
Perplexity
35
42
Gemini
37
40
Claude
43
33
Grok
35

Key Details

Category
General
General
Tier
Emerging
Emerging
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.